Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The high affinity and specificity of peptides towards biological targets, in addition to their favorable pharmacological properties, has encouraged the development of many peptide-based pharmaceuticals, including peptide-based positron emission tomography (PET) radiopharmaceuticals. However, the poor in vivo stability of unmodified peptides against proteolysis is a major challenge that must be overcome, as it can result in an impractically short in vivo biological half-life and a subsequently poor bioavailability when used in imaging and therapeutic applications. Consequently, many biologically and pharmacologically interesting peptide-based drugs may never see application. A potential way to overcome this is using peptide analogues designed to mimic the pharmacophore of a native peptide while also containing unnatural modifications that act to maintain or improve the pharmacological properties. This review explores strategies that have been developed to increase the metabolic stability of peptide-based pharmaceuticals. It includes modifications of the C- and/or N-termini, introduction of d- or other unnatural amino acids, backbone modification, PEGylation and alkyl chain incorporation, cyclization and peptide bond substitution, and where those strategies have been, or could be, applied to PET peptide-based radiopharmaceuticals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radzicka, A., & Wolfenden, R. (1996) · Journal of the American Chemical Society · doi:10.1021/ja954077c · Cited by 484 · cited 1×
“Normally, the peptide amide bond is stable to hydrolysis, requiring harsh conditions involving concentrated acids or bases at increased temperatures [38,39].”
BackgroundSystematic Analysis of Helical Protein Interfaces Reveals Targets for Synthetic Inhibitors
Jochim, A. L., & Arora, P. S. (2010) · ACS Chemical Biology · doi:10.1021/cb1001747 · Cited by 191
Uppalapati, M., Lee, D. J., Mandal, K., Li, H., Miranda, L. P., Lowitz, J., Kenney, J., Adams, J. J., Ault-Riché, D., Kent, S. B. H., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.5b01006 · Cited by 113 · cited 2×
“The result of this lack of recognition is that while most l-peptides are vul erable to nzymatic degradation i vivo [22], analogous d-peptid are highly esistant to degradatio by proteases and have low immunogenicity [47,48].”
Background
Cited by
Influences on PET Quantification and Interpretation
Rogasch, J. M. M., Hofheinz, F., van Heek, L., Voltin, C.-A., Boellaard, R., & Kobe, C. (2022) · Diagnostics · doi:10.3390/diagnostics12020451 · Cited by 57
“These include physiological and pharmacological factors [31], the in vivo degradation of peptide-based PET radiopharmaceuticals [32], and interactions between the lesion microenvironment and radiopharmaceuticals [33–36].”
BackgroundArtificial Intelligence and the Future of Diagnostic and Therapeutic Radiopharmaceutical Development
Ataeinia, B., & Heidari, P. (2021) · PET Clinics · doi:10.1016/j.cpet.2021.06.008 · Cited by 31
Dermawan, D., & Alotaiq, N. (2025) · Scientific Reports · doi:10.1038/s41598-025-93683-1 · Cited by 19
Metadata
- Authors
- Evans, B. J., King, A. T., Katsifis, A., Matesic, L., & Jamie, J. F.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-05-14
- Volume
- 25
- Issue
- 10
- Pages
- 2314
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W3025708624
- Cited by
- 154
- References
- 3
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals. https://app.cochat.ai/papers/10.3390/molecules25102314
- The paper
- Evans, B. J., King, A. T., Katsifis, A., Matesic, L., & Jamie, J. F. (2020). Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals. Molecules. https://doi.org/10.3390/molecules25102314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.